Estimating the budget impact of adopting tenofovir/emtricitabine for pre-exposure prophylaxis of HIV in the public health sector in Namibia (2021 – 2023)

Thumbnail Image

Files

moyo_estimating the budget impact of adopting tenofovir_2022.pdf (410.83 KB)

Date

2022

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier

Abstract

Namibia started implementing pre-exposure prophylaxis (PrEP) of Human Immunodeficiency Virus (HIV) in 2016, no study to determine its budget impact has been conducted. This study, therefore, aimed to estimate the budget impact of adopting tenofovir/emtricitabine for PrEP of HIV for all eligible people in the public health sector in Namibia from 2021 to 2023. Methods: A country-specific model was developed for this budget impact analysis (BIA). PrEP has targeted all eligible people in Namibia who receive health services from the public sector. It was assumed that the adherence rate was 75% and PrEP effectiveness 60% in this study. Costs used in this study were taken from a study that included Namibian costs.

Description

Keywords

HIV, Public health, PrEP, Namibia, Public sector

Citation

Moyo, E. et al. (2022). Estimating the budget impact of adopting tenofovir/emtricitabine for pre-exposure prophylaxis of HIV in the public health sector in Namibia (2021 – 2023). Journal of Infection and Public Health, 15(10), 1147-1155. https://doi.org/10.1016/j.jiph.2022.09.003

URI

https://doi.org/10.1016/j.jiph.2022.09.003
 http://hdl.handle.net/10566/8000

Collections

Research Articles (School of Public Health)